Skip to main content

Table 1 (abstract P96). Patient‑reported outcome (PRO) measures in patients with migraine who experience ≥4 migraine headache days/month and <4 migraine headache days/month in the US and in five European countries

From: 12th European Headache Federation Congress jointly with 32nd National Congress of the Italian Society for the Study of Headaches

  US Population 5-EU Population
≥4 MHDs/ month < 4 MHDs/ month ≥4 MHDs/ month < 4 MHDs/ month
(n=584) (n=789) (n=1942) (n=2147)
Disability Category by MIDAS Value, n (%)
 Little/No 102 (41.5) 291 (69.5) 247 (35.2) 477 (56.4)
 Mild 57 (23.2) 62 (14.8) 127 (18.1) 150 (17.8)
 Moderate 40 (16.3) 44 (10.5) 182 (26.0) 127 (15.0)
 Severe 30 (12.2) 18 ( 4.3) 101 (14.4) 77 ( 9.1)
 Very severe 17 ( 6.9) 4 ( 1.0) 44 ( 6.3) 14 ( 1.7)
MSQ Domain, Mean (SD)
 Total 67.6 (21.2) 78.8 (19.1) 67.7 (18.6) 76.1 (17.4)
 Role Function: Restrictive 63 (21.3) 75.6 (19.4) 64.2 (19.6) 72.4 (18.6)
 Role Function: Preventive 73.5 (21.9) 82.1 (20) 72.3 (19.8) 79.9 (17.9)
 Emotional 70.2 (24.9) 82 (22) 69.9 (21.8) 79.7 (19.8)
WPAI, Mean (SD)
 % work time missed due to problem 10.4 (22.8) 5.2 (18.1) 10 (21.4) 4 (13.7)
 % impairment while working due to problem 36.5 (28.3) 21.7 (24.1) 34.5 (22.5) 21.9 (22)
 % overall work impairment due to problem 40.3 (29.6) 22.7 (24.7) 39.7 (24.2) 23.4 (23.2)
 % activity impairment due to problem 38.6 (27.4) 25.3 (24.8) 39 (23.4) 27.7 (24)
EQ-5D-5L, Mean (SD)
 EQ5D Utility Score 0.9 (0.1) 0.9 (0.1) 0.8 (0.2) 0.9 (0.2)
 EQ5D Visual Analogue Scale 79.8 (14.7) 84.3 (13) 74.8 (15.8) 80.2 (15.4)
  1. All comparisons between patients with ≥4 MHDs/month and <4 MHDs/month are statistically significant (p<0.01; Chi-square test for MIDAS value, t-test for all other comparisons). The 5-EU population consists of the combined populations from Germany, France, UK, Italy and Spain. Abbreviation: MHD migraine headache days.